KYORIN Pharmaceutical Co., Ltd.

PickUp

These websites are only available in Japanese.

News Releases

February 4, 2026: Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Japanese GAAP]
February 4, 2026: Consolidated Financial Results for the Nine Months Ended December 31, 2025 - Supplementary Information
February 4, 2026: KYORIN Receives Regulatory Approval for influenza virus nucleic acid kit, GeneSoC FluAB Detection Kit
January 5, 2026: KYORIN and Lunatus Enter into Distribution Agreement for Lasvic Tablets in Nine Middle Eastern Countries
November 19, 2025: World's First Mitochondrial Disease Treatment 'MA-5' Commences Phase II Clinical Trial

About Kyorin

KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. Co., Ltd and has changed its trade name to “KYORIN Pharmaceutical. Co., Ltd.” on April 2023.

More detail

Investor Relations

This section provides information on the long-term vision, medium-term business plan, financial and performance results, IR library and stock.

More detail

Sustainability

Following our corperate philosophy, Kyorin Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.

More detail

R&D

A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.

More detail

PickUp

News Releases

Contens

About Kyorin

Investor Relations

Sustainability

R&D

Kyorin Group